RU2006115916A - Комбинированная терапия hcv инфекции - Google Patents
Комбинированная терапия hcv инфекции Download PDFInfo
- Publication number
- RU2006115916A RU2006115916A RU2006115916/15A RU2006115916A RU2006115916A RU 2006115916 A RU2006115916 A RU 2006115916A RU 2006115916/15 A RU2006115916/15 A RU 2006115916/15A RU 2006115916 A RU2006115916 A RU 2006115916A RU 2006115916 A RU2006115916 A RU 2006115916A
- Authority
- RU
- Russia
- Prior art keywords
- interferon
- therapeutic combination
- day
- patient
- combination according
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title claims 3
- 238000002648 combination therapy Methods 0.000 title claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 14
- 108010050904 Interferons Proteins 0.000 claims 9
- 102000014150 Interferons Human genes 0.000 claims 9
- 229940079322 interferon Drugs 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 5
- 229960000329 ribavirin Drugs 0.000 claims 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 5
- 108010078049 Interferon alpha-2 Proteins 0.000 claims 3
- 108010047761 Interferon-alpha Proteins 0.000 claims 3
- 102000006992 Interferon-alpha Human genes 0.000 claims 3
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 2
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 1
- 229960003521 interferon alfa-2a Drugs 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51073303P | 2003-10-11 | 2003-10-11 | |
| US60/510,733 | 2003-10-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006115916A true RU2006115916A (ru) | 2007-12-10 |
Family
ID=34465143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006115916/15A RU2006115916A (ru) | 2003-10-11 | 2004-10-12 | Комбинированная терапия hcv инфекции |
Country Status (17)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4080541B2 (ja) | 1996-10-18 | 2008-04-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子 |
| SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| TWI359147B (en) | 2003-09-05 | 2012-03-01 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv n |
| US20120201883A1 (en) * | 2004-05-21 | 2012-08-09 | Accu-Break Technologies, Inc | Antiviral compositons |
| TWI437990B (zh) * | 2004-10-29 | 2014-05-21 | Vertex Pharma | Vx-950之醫藥用途 |
| CA2617679A1 (en) * | 2005-08-02 | 2007-02-08 | Steve Lyons | Inhibitors of serine proteases |
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| JP2009531315A (ja) | 2006-03-16 | 2009-09-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | 重水素化ｃ型肝炎プロテアーゼインヒビター |
| WO2008106058A2 (en) * | 2007-02-27 | 2008-09-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| FR2928146B1 (fr) * | 2008-02-28 | 2010-02-19 | Saint Gobain Isover | Produit a base de fibres minerales et son procede d'obtention. |
| JP5539363B2 (ja) * | 2008-09-17 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インターフェロンおよびリバビリンとのｈｃｖｎｓ３プロテアーゼ阻害剤の組合せ |
| JP2012517478A (ja) * | 2009-02-12 | 2012-08-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤 |
| EP2450051A4 (en) * | 2009-06-30 | 2012-12-19 | Meiji Seika Pharma Co Ltd | MEDICAL AGENT AND METHOD FOR THE TREATMENT OF HARD-ANGLE CHRONIC HEPATITIS C |
| US20110027229A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients |
| PH12012500827A1 (en) | 2009-10-30 | 2013-01-07 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
| GB2506086A (en) | 2011-10-21 | 2014-03-19 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| WO2017062840A1 (en) * | 2015-10-09 | 2017-04-13 | Trek Therapeutics, Pbc | Combination therapy for the treatment of hepatitis c virus |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2017223178A1 (en) * | 2016-06-21 | 2017-12-28 | Trek Therapeutics, Pbc | Treating viral infections with impdh inhibitors |
| KR101991365B1 (ko) * | 2017-03-14 | 2019-06-21 | 국립암센터 | C형 간염 바이러스 질환 치료를 위한 리고세르팁의 신규 용도 |
| CN109745315B (zh) * | 2019-03-08 | 2021-04-16 | 中国农业科学院兰州兽医研究所 | 一种Merimepodib在制备预防口蹄疫病毒感染的药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL126674A (en) * | 1996-04-23 | 2005-08-31 | Vertex Pharma | Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives |
| IL139220A0 (en) * | 1998-05-15 | 2001-11-25 | Schering Corp | Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection |
| US6824769B2 (en) * | 2001-08-28 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Optimal compositions and methods thereof for treating HCV infections |
| US20040034206A1 (en) * | 2002-05-31 | 2004-02-19 | Schering Corporation | Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors |
-
2004
- 2004-10-08 AR ARP040103677A patent/AR045870A1/es not_active Application Discontinuation
- 2004-10-11 PE PE2004000979A patent/PE20050477A1/es not_active Application Discontinuation
- 2004-10-11 TW TW093130756A patent/TW200528104A/zh unknown
- 2004-10-12 US US10/964,243 patent/US20050112093A1/en not_active Abandoned
- 2004-10-12 AU AU2004281747A patent/AU2004281747A1/en not_active Abandoned
- 2004-10-12 JP JP2006534467A patent/JP2007508326A/ja active Pending
- 2004-10-12 KR KR1020067006996A patent/KR20060120037A/ko not_active Withdrawn
- 2004-10-12 ZA ZA200602912A patent/ZA200602912B/en unknown
- 2004-10-12 CA CA002541857A patent/CA2541857A1/en not_active Abandoned
- 2004-10-12 RU RU2006115916/15A patent/RU2006115916A/ru not_active Application Discontinuation
- 2004-10-12 EP EP04794964A patent/EP1670462A1/en not_active Withdrawn
- 2004-10-12 WO PCT/US2004/033739 patent/WO2005037274A1/en not_active Ceased
- 2004-10-12 CN CNA2004800335847A patent/CN1882335A/zh active Pending
- 2004-10-12 MX MXPA06004077A patent/MXPA06004077A/es not_active Application Discontinuation
- 2004-10-12 BR BRPI0415249-2A patent/BRPI0415249A/pt not_active Application Discontinuation
-
2006
- 2006-04-09 IL IL174864A patent/IL174864A0/en unknown
- 2006-05-10 NO NO20062104A patent/NO20062104L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2541857A1 (en) | 2005-04-28 |
| CN1882335A (zh) | 2006-12-20 |
| EP1670462A1 (en) | 2006-06-21 |
| PE20050477A1 (es) | 2005-08-24 |
| AU2004281747A1 (en) | 2005-04-28 |
| IL174864A0 (en) | 2008-04-13 |
| ZA200602912B (en) | 2007-06-27 |
| TW200528104A (en) | 2005-09-01 |
| US20050112093A1 (en) | 2005-05-26 |
| WO2005037274A1 (en) | 2005-04-28 |
| BRPI0415249A (pt) | 2006-12-12 |
| JP2007508326A (ja) | 2007-04-05 |
| AR045870A1 (es) | 2005-11-16 |
| MXPA06004077A (es) | 2006-06-27 |
| KR20060120037A (ko) | 2006-11-24 |
| NO20062104L (no) | 2006-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006115916A (ru) | Комбинированная терапия hcv инфекции | |
| RU2007105354A (ru) | Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv) | |
| JP2008518943A5 (cg-RX-API-DMAC7.html) | ||
| AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
| RU2007119725A (ru) | Лекарственные формы | |
| JP2002515453A5 (cg-RX-API-DMAC7.html) | ||
| BR0114636A (pt) | Terapia combinada para hcv de interferon-alfa peguilado/ribavirina | |
| TW200716095A (en) | Method of treating interferon non-responders using HCV protease inhibitor | |
| HUP0003384A2 (hu) | Legalább egy, kettős szálú RNS és legalább egy, vírus elleni szer kombinációját tartalmazó termék | |
| RU2011139180A (ru) | Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции | |
| NZ502740A (en) | Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection | |
| RU2010153688A (ru) | Режим дозирования телапревира | |
| JP2005516041A5 (cg-RX-API-DMAC7.html) | ||
| Manns et al. | Phase III results of Boceprevir in treatment naive patients with chronic hepatitis C genotype 1 | |
| PE20001386A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa | |
| JP2013542206A (ja) | Ｃ型肝炎ウイルス感染症の新規治療 | |
| WO2009067225A4 (en) | Boceprevir derivatives for the treatment of hcv infections | |
| Shobokshi et al. | 996 Combination therapy of peginterferon alfa-2A (40KD)(PEGASYS (R)) and ribavirin (COPEGUS (R)) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia | |
| JP2001288110A5 (cg-RX-API-DMAC7.html) | ||
| WO2005016288A3 (en) | Methods and compositions for treatment of viral diseases | |
| JP2004529158A5 (cg-RX-API-DMAC7.html) | ||
| RU2008109649A (ru) | ПЭГ-IFNα И РИБАВИРИН ДЛЯ ЛЕЧЕНИЯ ВИРУСА ГЕПАТИТА В | |
| WO2005120540A3 (en) | Interferon alpha or beta for treatment of cardiomyopathy and endothelial dysfunction | |
| DK1311279T3 (da) | Behandling af hepatitis C med thymosin, interferon og ribavirin | |
| Lawitz et al. | 997 Triple therapy compared to standard pegylated interferon alfa 2B+ weight based ribavirin for treatment naive chronic hepatitis C [tri-star trial]: final results |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090326 |